Zepatier

grazoprevir/elbasvir, or GZR/EBR

FDA approved for use in HIV/HCV co-infection
Genotype
  • 1
  • 4

Standard Dose

One tablet once daily with or without food. Each tablet contains 100 mg of grazoprevir and 50 mg of elbasvir. Ribavirin may be added in patients with certain baseline NS5A polymorphisms (mutations that may make the Zepatier less effective).

Zepatier can be used in severe renal impairment, including in patients on hemodialysis. NS3/4A protease inhibitors, such as grazoprevir, are contraindicated in patients with moderate or severe liver impairment (Child-Pugh B/C), which is also called decompensated cirrhosis. Using Zepatier in decompensated cirrhosis may cause significantly higher amounts of grazoprevir in the blood and may increase ALT (liver enzyme).

Take your missed dose as soon as possible, unless it is closer to the time of your next dose. Do not double up on your next dose.

BLACK BOX WARNING

Before starting treatment with any direct-acting antiviral (DAA), including Zepatier, patients should take a blood test to check for hepatitis B (HBV) infection. HBV infection could get worse or reactivate during or after DAA treatment, potentially leading to serious liver problems, including liver failure or death. Patients with current or past HBV infection should be monitored during HCV DAA treatment, and some may need to take HBV treatment. See HBV Reactivation for more information and consult your medical provider.

Manufacturer

Merck Pharmaceuticals

AWP

$21,840 / month

Potential Side Effects and Toxicity

Potential Drug Interactions

More Information